An observational study investigating and auditing the safety, tolerability and further efficacy characteristics of a pharmaceutical grade cannabis medicine (NanaBis™) prescribed to eligible patients for the management of cancer related and non-cancer related pain in general and specialty medical practices.
NanaBisTM is an investigative new product containing 1:1 ratio of Cannabidiol (CBD) and delta-9-trethydrocannabinol (THC), in a sub-micron spray applied to the oro-buccal membrane.
17 June 2019
National Institute of Integrative Medicine (NIIM) EC00436
Australian general and specialty medical practices.